Cargando…
EUROmediCAT signal detection: an evaluation of selected congenital anomaly‐medication associations
AIMS: To evaluate congenital anomaly (CA)‐medication exposure associations produced by the new EUROmediCAT signal detection system and determine which require further investigation. METHODS: Data from 15 EUROCAT registries (1995–2011) with medication exposures at the chemical substance (5th level of...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5137835/ https://www.ncbi.nlm.nih.gov/pubmed/27028286 http://dx.doi.org/10.1111/bcp.12947 |
_version_ | 1782471964458221568 |
---|---|
author | Given, Joanne E. Loane, Maria Luteijn, Johannes M. Morris, Joan K. de Jong van den Berg, Lolkje T.W. Garne, Ester Addor, Marie‐Claude Barisic, Ingeborg de Walle, Hermien Gatt, Miriam Klungsoyr, Kari Khoshnood, Babak Latos‐Bielenska, Anna Nelen, Vera Neville, Amanda J. O'Mahony, Mary Pierini, Anna Tucker, David Wiesel, Awi Dolk, Helen |
author_facet | Given, Joanne E. Loane, Maria Luteijn, Johannes M. Morris, Joan K. de Jong van den Berg, Lolkje T.W. Garne, Ester Addor, Marie‐Claude Barisic, Ingeborg de Walle, Hermien Gatt, Miriam Klungsoyr, Kari Khoshnood, Babak Latos‐Bielenska, Anna Nelen, Vera Neville, Amanda J. O'Mahony, Mary Pierini, Anna Tucker, David Wiesel, Awi Dolk, Helen |
author_sort | Given, Joanne E. |
collection | PubMed |
description | AIMS: To evaluate congenital anomaly (CA)‐medication exposure associations produced by the new EUROmediCAT signal detection system and determine which require further investigation. METHODS: Data from 15 EUROCAT registries (1995–2011) with medication exposures at the chemical substance (5th level of Anatomic Therapeutic Chemical classification) and chemical subgroup (4th level) were analysed using a 50% false detection rate. After excluding antiepileptics, antidiabetics, antiasthmatics and SSRIs/psycholeptics already under investigation, 27 associations were evaluated. If evidence for a signal persisted after data validation, a literature review was conducted for prior evidence of human teratogenicity. RESULTS: Thirteen out of 27 CA‐medication exposure signals, based on 389 exposed cases, passed data validation. There was some prior evidence in the literature to support six signals (gastroschisis and levonorgestrel/ethinylestradiol (OR 4.10, 95% CI 1.70–8.53; congenital heart disease/pulmonary valve stenosis and nucleoside/tide reverse transcriptase inhibitors (OR 5.01, 95% CI 1.99–14.20/OR 28.20, 95% CI 4.63–122.24); complete absence of a limb and pregnen (4) derivatives (OR 6.60, 95% CI 1.70–22.93); hypospadias and pregnadien derivatives (OR 1.40, 95% CI 1.10–1.76); hypospadias and synthetic ovulation stimulants (OR 1.89, 95% CI 1.28–2.70). Antipropulsives produced a signal for syndactyly while the literature revealed a signal for hypospadias. There was no prior evidence to support the remaining six signals involving the ordinary salt combinations, propulsives, bulk‐forming laxatives, hydrazinophthalazine derivatives, gonadotropin releasing hormone analogues and selective serotonin agonists. CONCLUSION: Signals which strengthened prior evidence should be prioritized for further investigation, and independent evidence sought to confirm the remaining signals. Some chance associations are expected and confounding by indication is possible. |
format | Online Article Text |
id | pubmed-5137835 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-51378352016-12-15 EUROmediCAT signal detection: an evaluation of selected congenital anomaly‐medication associations Given, Joanne E. Loane, Maria Luteijn, Johannes M. Morris, Joan K. de Jong van den Berg, Lolkje T.W. Garne, Ester Addor, Marie‐Claude Barisic, Ingeborg de Walle, Hermien Gatt, Miriam Klungsoyr, Kari Khoshnood, Babak Latos‐Bielenska, Anna Nelen, Vera Neville, Amanda J. O'Mahony, Mary Pierini, Anna Tucker, David Wiesel, Awi Dolk, Helen Br J Clin Pharmacol Pharmacoepidemiology AIMS: To evaluate congenital anomaly (CA)‐medication exposure associations produced by the new EUROmediCAT signal detection system and determine which require further investigation. METHODS: Data from 15 EUROCAT registries (1995–2011) with medication exposures at the chemical substance (5th level of Anatomic Therapeutic Chemical classification) and chemical subgroup (4th level) were analysed using a 50% false detection rate. After excluding antiepileptics, antidiabetics, antiasthmatics and SSRIs/psycholeptics already under investigation, 27 associations were evaluated. If evidence for a signal persisted after data validation, a literature review was conducted for prior evidence of human teratogenicity. RESULTS: Thirteen out of 27 CA‐medication exposure signals, based on 389 exposed cases, passed data validation. There was some prior evidence in the literature to support six signals (gastroschisis and levonorgestrel/ethinylestradiol (OR 4.10, 95% CI 1.70–8.53; congenital heart disease/pulmonary valve stenosis and nucleoside/tide reverse transcriptase inhibitors (OR 5.01, 95% CI 1.99–14.20/OR 28.20, 95% CI 4.63–122.24); complete absence of a limb and pregnen (4) derivatives (OR 6.60, 95% CI 1.70–22.93); hypospadias and pregnadien derivatives (OR 1.40, 95% CI 1.10–1.76); hypospadias and synthetic ovulation stimulants (OR 1.89, 95% CI 1.28–2.70). Antipropulsives produced a signal for syndactyly while the literature revealed a signal for hypospadias. There was no prior evidence to support the remaining six signals involving the ordinary salt combinations, propulsives, bulk‐forming laxatives, hydrazinophthalazine derivatives, gonadotropin releasing hormone analogues and selective serotonin agonists. CONCLUSION: Signals which strengthened prior evidence should be prioritized for further investigation, and independent evidence sought to confirm the remaining signals. Some chance associations are expected and confounding by indication is possible. John Wiley and Sons Inc. 2016-07-07 2016-10 /pmc/articles/PMC5137835/ /pubmed/27028286 http://dx.doi.org/10.1111/bcp.12947 Text en © 2016 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of The British Pharmacological Society This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Pharmacoepidemiology Given, Joanne E. Loane, Maria Luteijn, Johannes M. Morris, Joan K. de Jong van den Berg, Lolkje T.W. Garne, Ester Addor, Marie‐Claude Barisic, Ingeborg de Walle, Hermien Gatt, Miriam Klungsoyr, Kari Khoshnood, Babak Latos‐Bielenska, Anna Nelen, Vera Neville, Amanda J. O'Mahony, Mary Pierini, Anna Tucker, David Wiesel, Awi Dolk, Helen EUROmediCAT signal detection: an evaluation of selected congenital anomaly‐medication associations |
title | EUROmediCAT signal detection: an evaluation of selected congenital anomaly‐medication associations |
title_full | EUROmediCAT signal detection: an evaluation of selected congenital anomaly‐medication associations |
title_fullStr | EUROmediCAT signal detection: an evaluation of selected congenital anomaly‐medication associations |
title_full_unstemmed | EUROmediCAT signal detection: an evaluation of selected congenital anomaly‐medication associations |
title_short | EUROmediCAT signal detection: an evaluation of selected congenital anomaly‐medication associations |
title_sort | euromedicat signal detection: an evaluation of selected congenital anomaly‐medication associations |
topic | Pharmacoepidemiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5137835/ https://www.ncbi.nlm.nih.gov/pubmed/27028286 http://dx.doi.org/10.1111/bcp.12947 |
work_keys_str_mv | AT givenjoannee euromedicatsignaldetectionanevaluationofselectedcongenitalanomalymedicationassociations AT loanemaria euromedicatsignaldetectionanevaluationofselectedcongenitalanomalymedicationassociations AT luteijnjohannesm euromedicatsignaldetectionanevaluationofselectedcongenitalanomalymedicationassociations AT morrisjoank euromedicatsignaldetectionanevaluationofselectedcongenitalanomalymedicationassociations AT dejongvandenberglolkjetw euromedicatsignaldetectionanevaluationofselectedcongenitalanomalymedicationassociations AT garneester euromedicatsignaldetectionanevaluationofselectedcongenitalanomalymedicationassociations AT addormarieclaude euromedicatsignaldetectionanevaluationofselectedcongenitalanomalymedicationassociations AT barisicingeborg euromedicatsignaldetectionanevaluationofselectedcongenitalanomalymedicationassociations AT dewallehermien euromedicatsignaldetectionanevaluationofselectedcongenitalanomalymedicationassociations AT gattmiriam euromedicatsignaldetectionanevaluationofselectedcongenitalanomalymedicationassociations AT klungsoyrkari euromedicatsignaldetectionanevaluationofselectedcongenitalanomalymedicationassociations AT khoshnoodbabak euromedicatsignaldetectionanevaluationofselectedcongenitalanomalymedicationassociations AT latosbielenskaanna euromedicatsignaldetectionanevaluationofselectedcongenitalanomalymedicationassociations AT nelenvera euromedicatsignaldetectionanevaluationofselectedcongenitalanomalymedicationassociations AT nevilleamandaj euromedicatsignaldetectionanevaluationofselectedcongenitalanomalymedicationassociations AT omahonymary euromedicatsignaldetectionanevaluationofselectedcongenitalanomalymedicationassociations AT pierinianna euromedicatsignaldetectionanevaluationofselectedcongenitalanomalymedicationassociations AT tuckerdavid euromedicatsignaldetectionanevaluationofselectedcongenitalanomalymedicationassociations AT wieselawi euromedicatsignaldetectionanevaluationofselectedcongenitalanomalymedicationassociations AT dolkhelen euromedicatsignaldetectionanevaluationofselectedcongenitalanomalymedicationassociations |